股东减持计划时间届满未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 证券代码：600080 证券简称：金花股份 公告编号：2023-055 金花企业（集团）股份有限公司 (一)大股东及董监高因以下事项披露减持计划实施结果： 披露的减持时间区间届满 | 股东名称 | 减持数 | 减持 | 减持期间 | 减持方式 | 减持价格区间 | 减持总金 | 减持完成情况 | 当前持股 | 当前持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 量（股） | 比例 | | | （元/股） | 额（元） | | 数量（股） | 股比例 | | 新余兴鹏同创企业管理 | 0 | 0% | 2023/7/31～ | 集中竞价交 易、大宗交 | 0－0 | 0 | 未完成： | 6,238,427 | 1.67% | | 合伙企业（有限合伙） | | | 2023/10/31 | 易 | | | ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥147,435,488.04, a decrease of 10.34% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥347,660.30, down 96.64% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,603,942.65, a decline of 77.65% compared to the previous year[5] - The basic earnings per share for Q3 2023 was ¥0.0009, a decrease of 96.58% year-on-year[6] - Total operating revenue for the first three quarters of 2023 was CNY 402.81 million, a decrease of 4.5% compared to CNY 423.15 million in the same period of 2022[20] - Net profit for the third quarter of 2023 was CNY 3.39 million, a significant decline of 89.3% compared to CNY 31.83 million in the same quarter of 2022[22] - Basic earnings per share for the third quarter of 2023 were CNY 0.0091, down from CNY 0.0853 in the same quarter of 2022[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,058,831,041.90, an increase of 4.28% from the end of the previous year[6] - Total assets as of the end of the third quarter of 2023 were CNY 2.06 billion, an increase from CNY 1.97 billion at the end of the third quarter of 2022[18] - Total liabilities for the third quarter of 2023 amounted to CNY 371.68 million, up from CNY 290.65 million in the same period of 2022, representing a growth of 28%[18] - The company reported a total non-current asset of CNY 1.20 billion, an increase from CNY 1.03 billion in the previous year[18] - The company’s total equity as of the end of the third quarter of 2023 was CNY 1.69 billion, slightly up from CNY 1.68 billion in the same period of 2022[18] Cash Flow - The company reported a net cash flow from operating activities of -¥11,949,314.66, reflecting a decrease of 28.52% year-to-date[6] - In the first three quarters of 2023, the cash inflow from operating activities was CNY 441,830,298.33, slightly up from CNY 441,329,151.28 in the same period of 2022[23] - The net cash flow from operating activities was negative at CNY -11,949,314.66, compared to CNY -9,297,386.75 in the previous year[23] - The total cash inflow from investment activities was CNY 1,446,976,524.92, significantly higher than CNY 983,848,470.29 in the prior year[24] - The net cash flow from investment activities was CNY -48,514,725.24, a decline from CNY 64,166,189.36 in the same period last year[24] - The cash inflow from financing activities amounted to CNY 175,405,390.44, with a net cash flow of CNY 67,366,210.20, compared to a negative CNY -176,530.76 in the previous year[24] - The total cash and cash equivalents at the end of the period were CNY 439,540,865.47, up from CNY 213,132,731.53 at the end of the same period last year[24] Expenses and Investments - Research and development expenses increased by 37.95% year-to-date, attributed to higher investment in ongoing R&D projects[9] - The company reported a significant decrease in net profit due to increased expenses and reduced investment income, with a year-to-date decline of 89.35%[9] - The company’s financial expenses increased by 58.08% year-to-date, mainly due to higher interest expenses[9] - Research and development expenses increased to CNY 8.86 million in the third quarter of 2023, compared to CNY 6.42 million in the same quarter of 2022, marking a rise of 38.1%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27.854 million[11] - The largest shareholder, Xing Boyue, holds 19.63% of shares, totaling 73,272,546 shares[11] Strategic Initiatives - The company signed a cooperation agreement to establish the "Western Jinhua Academician Workstation" with Academician Wang Songling's team for drug research and development[13] - The company aims to enhance its technological innovation capabilities through the collaboration with Academician Wang's team[13] - The new drug research project is in the early stages and may be influenced by various factors, with uncertain success[14]

证券代码：600080 股票简称：金花股份 编号：临 2023-054 金花企业（集团）股份有限公司 第十届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司第十届董事会第四次会议通知于 2023 年 10 月 24 以电子邮件及微信方式发出，会议于 2023 年 10 月 26 日以通讯表决方式召开，应参 与表决董事 7 人，实际表决人数 7 人，符合《公司法》和《公司章程》的有关规定。 经讨论表决，会议通过如下决议。 二、董事会会议审议情况 （一）通过《公司 2023 年第三季度报告》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 《 2023 年 第 三 季 度 报 告 》 详 见 上 海 证 券 报 及 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）。 （二）通过《关于向银行申请综合授信的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 具体内容详见公司同日在上海证券报及上海证券交易所网站 ...

金花企业(集团)股份有限公司 证券代码：600080 股票简称：金花股份 编号：临 2023-053 关于向银行申请综合授信的公告 二、担保方式 1、公司以位于西安市高新区科技四路 202 号的办公用房及厂房提供抵押担 保。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 金花企业（集团）股份有限公司（以下简称"公司"）拟向银行申请 额度为 18600 万元的综合授信。 该事项已经公司第十届董事会第四次会议审议通过，无需提交股东大 会审议。 公司于2023年10月26日以通讯方式召开了第十届董事会第四次会议，审议通 过了《关于向银行申请综合授信的议案》。具体如下： 一、本次向银行申请综合授信的基本情况 根据经营和业务发展需要，公司拟向齐商银行股份有限公司西安分行申请额 度为 18600 万元的综合授信，主要包括流动资金贷款、银行承兑汇票、信用证、 保函、中期票据等业务，期限 12 个月，在授信期限内，该授信额度可循环使用， 具体贷款额度、利率等以银行审批及最终签署的合同为准，使用金额以公司资金 的实际需求 ...

证券代码：600080 股票简称：金花股份 编号：临 2023-052 金花企业（集团）股份有限公司 关于转让参股公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 金花企业（集团）股份有限公司（以下简称"公司"）于 2023 年 9 月 8 日 召开第十届董事会第三次会议，审议通过了《关于转让参股公司股权的议案》， 同意将公司所持有的参股公司重庆医药集团陕西有限公司（以下简称"重药陕西 公司"）8.39%股权转让给陕西祥沣实业发展有限公司（以下简称"陕西祥沣"）， 转让价格为 1418 万元。具体内容详见公司于 2023 年 9 月 9 日在上海证券报及上 海证券交易所网站披露的《金花企业（集团）股份有限公司关于转让参股公司股 权的公告》（公告编号：临 2023-051 号）。 二、交易进展 截止目前，公司已收到陕西祥沣支付的重药陕西公司 8.39%股权全部转让 款，并办理完毕相关工商变更登记手续，本次转让事项已完成，公司将不再持有 重药陕西公司股权。 金花企业（集团）股份有限公司董事会 ...

证券代码：600080 股票简称：金花股份 编号：临 2023-051 金花企业（集团）股份有限公司 关于转让参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●交易简要内容：金花企业（集团）股份有限公司（以下简称"公司"）拟 将所持有的参股公司重庆医药集团陕西有限公司（以下简称"目标公司"或"重 药陕西公司"）8.39%股权转让给陕西祥沣实业发展有限公司（以下简称"陕西祥 沣"），交易价格以目标公司 2022 年度审计报告确认的净资产为作价依据，经双 方协商确定交易金额为 1418 万元。 ●本次交易不构成关联交易。 （一）本次交易的基本情况 ●相关风险提示：本次转让目标公司股权尚需办理工商过户手续，敬请广大 投资者，注意投资风险。 （三）审议情况及审批流程 ●本次交易不构成重大资产重组。 ●本次交易已经公司第十届董事会第三次会议审议通过，根据《上海证券交易 所股票上市规则》及《公司章程》等相关规定，本次交易无需提交股东大会审议。 公司拟将所持有的参股公司重药陕西公司 8.39%股权转 ...

陕西博硕律师事务所 关于金花企业（集团）股份有限公司 2023 年第一次临时股东大会的法律意见书 致：金花企业（集团）股份有限公司 根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人民共和 国公司法》（以下简称《公司法》）和中国证券监督管理委员会《上市公司股东 大会规则》（以下简称《股东大会规则》）等法律、行政法规、规范性文件及《金 花企业（集团）股份有限公司章程》（以下简称《公司章程》）的规定，陕西博 硕律师事务所（以下简称本所）接受金花企业（集团）股份有限公司（以下简称 公司）的委托，指派律师出席公司 2023 年第一次临时股东大会（以下简称本次 股东大会）。 本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资格、召 集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会审议的议案 所涉及的数字及内容发表意见。本所律师同意将本法律意见书随本次股东大会其 他信息披露资料一并公告。本法律意见书仅供见证公司本次股东大会相关事项的 合法性之目的使用，不得用作任何其他目的。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本 ...

证券代码：600080 证券简称：金花股份 公告编号：2023-050 金花企业（集团）股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 11 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 128,578,960 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 34.4466 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采取现场和网络投票相结合的方式召开，由董 (一) 股东大会召开的时间：2023 年 9 月 4 日 (二) 股东大会召开的地点：陕西省西安市高新三路财富中心三期南座 40 层会 议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 事长邢雅江先生主持本次股东大会，现场会议采取记名 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥255.37 million, a decrease of 1.29% compared to ¥258.72 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥3.04 million, representing a significant decline of 85.83% from ¥21.47 million in the previous year[21]. - The basic earnings per share for the first half of 2023 was ¥0.0082, down 85.74% from ¥0.0575 in the same period last year[21]. - The net cash flow from operating activities for the first half of 2023 was negative at approximately -¥34.39 million, compared to a positive cash flow of ¥24.25 million in the previous year[21]. - The total assets as of June 30, 2023, were approximately ¥1.94 billion, a decrease of 1.78% from ¥1.97 billion at the end of the previous year[21]. - The net profit attributable to shareholders was 3.04 million yuan, a decrease of 85.83% year-on-year[31]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 17.41 million yuan, a decrease of 13.34% year-on-year[31]. - The company reported a significant reduction in other receivables, which fell to CNY 10,899,691.69 from CNY 165,246,367.76, a decrease of about 93.4%[102]. Research and Development - Research and development expenses increased by 32.10% to ¥5,233,339.12 from ¥3,961,559.85 year-on-year, reflecting a commitment to innovation[41]. - The company is committed to improving its R&D capabilities by increasing investment and accelerating product development to address new product development risks[56]. - The company is committed to ongoing research and development to drive innovation and competitiveness in the market[128]. Market Position and Strategy - The company’s main product, Jintian Ge Capsule, is recognized as a first-class new drug in the country and has established a competitive advantage in the orthopedic clinical market[28]. - The company’s marketing network covers the entire country, utilizing a professional academic promotion approach[30]. - The company is positioned in a strategic industry that is expected to benefit from ongoing healthcare reforms and policy support in the pharmaceutical sector[26]. - The company aims to enhance its brand recognition, with its "Jinhua" trademark recognized as a famous brand in China, contributing to its competitive edge[36]. - The company is actively pursuing digital transformation and collaboration with online service platforms to improve market reach and operational efficiency[38]. Financial Health and Investments - The net cash flow from investment activities for the first half of 2023 was ¥77,884,051.05, an increase from ¥24,110,855.87 in the previous period[42]. - Long-term equity investments increased by 54.84% to ¥495,192,417.59, attributed to increased investments in joint ventures[44]. - The company completed significant equity investments totaling ¥170,000,000 in three new subsidiaries during the reporting period[48]. - The company is focusing on expanding its non-current asset investments, particularly in long-term equity investments, which increased to CNY 495,192,417.59 from CNY 319,801,943.72, a growth of approximately 55%[102]. Environmental Compliance - The company has maintained compliance with environmental standards, with wastewater discharge showing a pH of 7.6 and CODcr concentration of 167 mg/L, totaling approximately 2.58 tons[69]. - The nitrogen oxide emissions from the natural gas boiler have been reduced to no more than 80 mg/m3 following low-nitrogen modifications[69]. - The company has successfully implemented measures to ensure that all pollutants are within the allowable limits set by environmental regulations[69]. - The company has established a dedicated team for the maintenance and operation of its environmental protection facilities, ensuring their effective functioning[69]. Legal and Regulatory Matters - The company received disciplinary actions from the China Securities Regulatory Commission and the Shanghai Stock Exchange, emphasizing the need for compliance and corrective measures[83]. - A total of 245 lawsuits were filed by investors against the company for false statements, with 182 cases settled and 51 cases executed by final judgment, all of which have been concluded[81]. - The company has engaged in significant related party transactions, with a total of 3,181,456.37 RMB in transactions reported, including various rental and service agreements[84]. - The company has taken steps to address the illegal guarantee issue, including a detailed announcement on February 11, 2023, regarding the original actual controller's actions[80]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 28,078[91]. - The largest shareholder, Xing Boyue, holds 73,272,546 shares, representing 19.63% of the total shares, with 53,273,495 shares pledged[93]. - Century Jinhua Co., Ltd. decreased its holdings by 3,766,700 shares, holding 22,672,600 shares, which is 6.07% of the total[93]. - The company reported no changes in total share capital and structure during the reporting period[89]. Accounting Policies and Financial Reporting - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[137]. - The company adheres to the enterprise accounting standards, ensuring that the financial reports accurately reflect its financial status and performance[139]. - The company recognizes expected credit losses for contract assets in accordance with the same principles applied to accounts receivable, ensuring accurate financial reporting[171]. - The company applies a perpetual inventory system for its inventory, using a weighted average method for cost determination[169].

证券代码：600080 证券简称：金花股份 公告编号：2023-048 金花企业（集团）股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 9 月 4 日 13 点 30 分 召开地点：陕西省西安市高新三路财富中心三期南座 40 层会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2023年9月4日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 二、 会议审议事项 本次股东大会审议议案及投票股东类型 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 4 日 至 2023 年 9 月 4 日 采用上海证 ...